N,N-dimethyl-4-(pyrrolidin-1-yl)aniline | 79850-90-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: N,N-dimethyl-4-(pyrrolidin-1-yl)aniline
• 英文别名: N,N-dimethyl-4-pyrrolidin-1-ylaniline
• CAS: 79850-90-1
• 化学式: C₁₂H₁₈N₂
• 分子量: 190.288
• InChiKey: YQETXHVLPRBMJV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  6.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  四氢呋喃 、 N,N-二甲基-对苯二胺 在 1,8-二氮杂双环[5.4.0]十一碳-7-烯 、 三氯氧磷 作用下， 以 5,5-dimethyl-1,3-cyclohexadiene 为溶剂， 反应 15.25h， 以76%的产率得到N,N-dimethyl-4-(pyrrolidin-1-yl)aniline
  参考文献：
  名称：

  使用POCl 3从环状醚中无金属合成N-芳基取代的氮杂环化合物

  摘要：

  已经开发了一种从芳基胺和环醚合成N-芳基取代的氮杂环化合物的简便方法。在这项研究中，芳基胺在POCl 3和DBU的存在下用环醚处理，以提供五元和六元氮杂环。使用这种方法，可以高收率制备各种氮杂环烷烃，异吲哚啉和四氢异喹啉。这种合成方法为由环醚生产氮杂环化合物提供了一种有效的方法。

  DOI：

  10.1021/acs.joc.9b00377

文献信息

• Amide Substituted Indazole and Benzotriazole Derivatives as Poly(ADP-Ribose)Polymerase (PARP) Inhibitors
  申请人：Boueres Julia

  公开号：US20090275619A1

  公开（公告）日：2009-11-05

  The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts or tautomers thereof which are inhibitors of poly (ADP-ribose) polymerase (PARP) and thus useful for the treatment of cancer, inflammatory diseases, reperfusion injuries, ischemic conditions, stroke, renal failure, cardiovascular diseases, vascular diseases other than cardiovascular diseases, diabetes, neurodegenerative diseases, retroviral infection, retinal damage or skin senescence and UV-induced skin damage, and as chemo- or radiosensitizers for cancer treatment.

  本发明涉及式(I)化合物及其药学上可接受的盐或互变异构体，它们是聚(ADP-核糖)聚合酶(PARP)的抑制剂，因此可用于治疗癌症、炎症性疾病、再灌注损伤、缺血性疾病、中风、肾衰竭、心血管疾病、除心血管疾病外的血管疾病、糖尿病、神经退行性疾病、逆转录病毒感染、视网膜损伤或皮肤衰老和紫外线诱导的皮肤损伤的治疗，以及作为化疗或放疗增敏剂用于癌症治疗。
• AMIDE SUBSTITUTED INDAZOLE AND BENZOTRIAZOLE DERIVATIVES AS POLY(ADP-RIBOSE)POLYMERASE (PARP) INHIBITORS
  申请人：Boueres Julia

  公开号：US20110201657A1

  公开（公告）日：2011-08-18

  The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts or tautomers thereof which are inhibitors of poly (ADP-ribose) polymerase (PARP) and thus useful for the treatment of cancer, inflammatory diseases, reperfusion injuries, ischemic conditions, stroke, renal failure, cardiovascular diseases, vascular diseases other than cardiovascular diseases, diabetes, neurodegenerative diseases, retroviral infection, retinal damage or skin senescence and UV-induced skin damage, and as chemo- or radiosensitizers for cancer treatment.

  本发明涉及公式（I）的化合物及其药学上可接受的盐或互变异构体，这些化合物是聚（ADP核糖）聚合酶（PARP）的抑制剂，因此可用于治疗癌症、炎症性疾病、再灌注损伤、缺血性疾病、中风、肾衰竭、心血管疾病、除心血管疾病外的其他血管疾病、糖尿病、神经退行性疾病、逆转录病毒感染、视网膜损伤或皮肤衰老和紫外线诱导的皮肤损伤的治疗，以及作为癌症治疗的化疗或放疗增敏剂。
• SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES
  申请人：Incyte Corporation

  公开号：US20150025056A1

  公开（公告）日：2015-01-22

  The present invention provides compounds of the formula I: its enantiomers, diastereomers, racemic mixtures thereof, prodrugs, crystalline forms, non-crystalline forms, amorphous forms thereof, solvates thereof, metabolites thereof, and pharmaceutically acceptable salts, wherein the ring A substituent groups are fully defined in the following disclosure. The compounds of formula I are inhibitors of metalloproteases such as matrix metalloproteases and sheddases, and are useful in treating diseases such as rheumatoid arthritis, psoriasis, neoplastic diseases, allergies and all those diseases wherein inhibition of MMPs is desirable.

  本发明提供了I式化合物：其对映异构体，对映体混合物，前药，结晶形式，非晶形式，无定形形式，其溶剂化物，其代谢物和药学上可接受的盐，其中环A取代基团在以下披露中得到充分定义。I式化合物是金属蛋白酶抑制剂，如基质金属蛋白酶和剪切酶的抑制剂，并且在治疗风湿性关节炎，牛皮癣，肿瘤性疾病，过敏和所有需要抑制MMP的疾病中有用。
• Thiophene and Thiazole Substituted trifluoroethanone Derivatives as Histone Deacetylase (Hdac) Inhibitors
  申请人：Ferrigno Federica

  公开号：US20090156591A1

  公开（公告）日：2009-06-18

  The present invention relates to compounds of formula (I): or a pharmaceutically acceptable salt or stereoisomer thereof. The compounds of the present invention are inhibitors of histone deacetylase (HDAC) and are useful for treating cellular proliferative diseases, including cancer. Further, the compounds of the present invention are useful for treating neurodegenerative diseases, schizophrenia and stroke among other diseases.

  本发明涉及式(I)的化合物，或其药学上可接受的盐或立体异构体。本发明的化合物是组蛋白去乙酰化酶（HDAC）的抑制剂，可用于治疗细胞增殖性疾病，包括癌症。此外，本发明的化合物还可用于治疗神经退行性疾病、精神分裂症和中风等其他疾病。
• Preparation and Properties of N,N,N',N'-Tetrasubstituted 1,4-Benzenediamines.
  作者：Jørn B. Christensen、Niels-Christian Schiødt、Klaus Bechgaard、Thomas Buch-Rasmussen、Ward T. Robinson、David J. Timmerman-Vaughan、Muhammed Nour Homsi、Frank K. H. Kuske、Monika Haugg、Nathalie Trabesinger-Rüf、Elmar G. Weinhold

  DOI：10.3891/acta.chem.scand.50-1013

  日期：——

  The synthesis of nine different N,N,N',N'-tetrasubstituted 1,4-benzenediamines is described. These compounds are of interest as mediators for glucose oxidase based biosensors and as donor molecules for conducting molecular solids. The electrochemical behaviour and the electronic absorption spectra have been investigated.